Antigen processing and presentation in HIV infection

Julie Boucau, Sylvie Le Gall*

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, United States

ABSTRACT

The presentation of virus-derived peptides by MHC molecules constitutes the earliest signals for immune recognition by T cells. In HIV infection, immune responses elicited during infection do not enable to clear infection and correlates of immune protection are not well defined. Here we review features of antigen processing and presentation specific to HIV, analyze how HIV has adapted to the antigen processing machinery and discuss how advances in biochemical and computational protein degradation analyses and in immunopeptidome definition may help identify targets for efficient immune clearance and vaccine immunogen design.

1. HIV traffic and antigen processing pathways in cell subsets

The antigen processing machinery serves many purposes critical to cell maintenance, degrading retiree and misfolded proteins, recycling amino acids for protein synthesis and producing peptides for MHC-I and MHC-II display and immune monitoring (Blum et al., 2013). Each subcellular compartment contains several proteases and peptidases involved in protein degradation. Cytosolic constitutive proteasomes and immunoproteasomes can unfold and degrade proteins into fragments further processed into peptides by cytosolic aminopeptidases and endopeptidases, some of which are transferred into the ER for further trimming by ER-resident aminopeptidases, ERAP1 and ERAP2, and loading onto MHC-I (Lazaro et al., 2015). Exogenous antigens such as proteins, free or antibody-coated viruses, cell debris endocytosed or phagocytosed may be degraded by cathepsins in endosomes and lysosomes. Degradation peptides transferred in the cytosol and endoplasmic reticulum (ER) for further degradation are cross-presented in the vesicular pathway by MHC-I or, in professional antigen presenting cells, transported into the MIIC compartment for MHC-II loading and presentation (Blum et al., 2013; Stern and Santambrogio, 2016; Vyas et al., 2008). MHC-II complexes also present endogenous antigens during autophagy, when cytosolic and nuclear antigens are engulfed in autophagosomes fusing with lysosomes for degradation and MHC-II presentation. Autophagy during HIV infection leads to HIV MHC-II presentation by dendritic cells (DC) (Coulon et al., 2016). Proteasomes, tripeptidyl peptidase II (TPPII), thimet oligopeptidase (TOP), nardilysin and ERAP1, cathepsins are involved in the processing of some HIV epitopes but few HIV epitopes have been studied with respect to peptidase requirements for production or degradation (Kessler et al., 2011; Steers et al., 2011, 2012; Le Gall et al., 2007; Tenzer et al., 2009). Direct

and cross-presentation pathways intersect in many points, as evidenced by the generation of MHC-II-restricted cancer antigen-derived epitopes requiring proteasome processing (Matsuzaki et al., 2014). The role of intracellular antigen traffic in the definition of the MHC peptidome and kinetics of presentation of peptides to immune cells is still poorly understood despite its critical role for immune recognition.

HIV infects cell subsets expressing CD4 and co-receptors CCR5 or CXCR4: CD4 T cells, monocytes, macrophages and dendritic cells (Law et al., 2016; DiNapoli et al., 2016). Productive infection requires that HIV fuses at the plasma membrane delivering the viral core into the cytosol, proceeds to uncoating and reverse transcription during its transport to the nucleus, and eventually the DNA provirus integrates into the cell genome. The provirus is eventually transcribed and translated into new proteins assembling into immature virions budding at the plasma membrane. Conversely, HIV provirus can enter quiescence and become part of reservoirs persisting despite antiretroviral treatments (Churchill et al., 2016; Martinez-Picado and Deeks, 2016). Productive infection is a rare event since many HIV entry events lead to abortive infection due to the antiviral activity of host restriction factors and of the degradation machinery (Chauveau et al., 2017; Marechal et al., 1998; Doitsh et al., 2010; Compton et al., 2014). Free HIV virions or antibody-coated particles may be endocytosed or phagocytosed and degraded into endolysosomes or phagosomes. Particles entering in the cytosol can also be subjected to degradation by proteasomes during uncoating (Schwartz et al., 1998). After provirus expression, neosynthesized proteins may be degraded and lead to MHC-I presentation (Schubert et al., 2000a,b; Schubert et al., 2000a,b), while autophagy in HIV-infected cells may lead to MHC-II presentation (Coulon et al., 2016). However, the exact peptides processed and presented by cells have not been extensively defined, rather mostly inferred based on T

cell responses in HIV-infected persons. Virus traffic influences both the outcome of viral replication and its degradation, but we still do not comprehend how it contributes to defining the HIV MHC-peptidome and the immunogenicity of HIV proteins. HIV proteins are variably immunogenic within an individual and at the population level (Llano et al., 2013). HIV Gag p24, Env, Nef are the most immunogenic while Tat or Vpu are poorly immunogenic. The density of putative MHC-I peptide anchors in HIV proteome and the conservation of the proteins across variants or strains do not fully account for such differences. The analysis of degradation patterns of HIV antigens by purified proteasomes (Steers et al., 2011, 2012; Tenzer et al., 2009; Choppin et al., 2001; Ranasinghe et al., 2011), or in the cytosol or endolysosomes of primary cells (Le Gall et al., 2007; Dinter et al., 2015, 2014; Kourjian et al., 2016, 2014) identifies areas of proteins quickly degraded into fragments too short be loaded onto MHC-I, while other areas are degraded slower and generate nested degradation peptides of various lengths. The timing of production of epitopes within a protein, even for overlapping epitopes, is variable and in part determined by motifs flanking epitopes (Le Gall et al., 2007). These variable degradation patterns and kinetics of production of epitopes may contribute to the variable density of CD8 immune responses within a HIV protein (Steers et al., 2012; Le Gall et al., 2007; Tenzer et al., 2009), but motifs predicting the production of degradation fragments of various lengths and peptide presentation by MHC-I or MHC-II remain to be identified. Aside from degradation patterns, the intracellular stability of degradation peptides also contribute to defining the amount of peptides available of MHC loading (Lazaro et al., 2011). The stability of short HIV peptides is surprisingly variable (few seconds to hour), defined by motifs associated with stability or instability. Algorithms like NetChOP predicting proteasomal cleavage sites (Nussbaum et al., 2001; Nielsen et al., 2007), sometime in combination with algorithms for TAP or MHC binding (Calis et al., 2015; Tenzer et al., 2005), help identify some degradation features. But they do not account for other peptidases involved in protein degradation (Lazaro et al., 2015), the specificity of the degradation machinery in each cell subset or cellular compartments (Steers et al., 2011; Dinter et al., 2015, 2014; Lazaro et al., 2009), and viral diversity. Comparison of HIV antigen degradation patterns in cytosol, endosomes and lysosomes identified expected variations in degradation patterns across compartments and showed that some epitopes were produced in all compartments while others were exclusively produced in the cytosol or in the endolysosomal compartment (Steers et al., 2012; Dinter et al., 2015, 2014; Kourjian et al., 2016, 2014). These data suggest that the traffic path followed by HIV after entry will shape not only the outcome of infection, but also the timing and nature of degradation peptides available for MHC presentation. Aside from differences during intracellular traffic, the different cell subsets targeted by the virus display variable levels of peptidases activities. As expected from studies in mice (Delamarre et al., 2005), macrophages present the highest levels of hydrolytic activities in endolysosomes in accordance with their clearance functions (Dinter et al., 2015, 2014). Dendritic cells present higher lysosomal activities than CD4 T cells but low cytosolic peptidase activities (Dinter et al., 2015, 2014; Lazaro et al., 2009; McCurley and Mellman, 2010). Differences in peptidase activities affected the degradation patterns of HIV antigens, the kinetics and amount of epitopes produced. While the surface peptidome of HIV-infected cell subsets has not yet been compared to matched CD4 T cells, DC, and macrophages, it is possible that differences in epitope production will affect the MHC-peptidome, and perhaps the efficiency of immune recognition of various cell subsets by epitope-specific CD8 T cells. Differences in antigen processing activities among cell subsets may be due to variable levels of expression of peptidases, and distinct and unknown mechanisms regulating peptidase hydrolytic activities across cell subsets. The variable effects of proteasome or cathepsin inhibitors on the processing and presentation of HIV peptides between matching monocyte-derived DC and macrophages suggest that various sets of peptidases are involved in the processing and/or degradation of

epitopes in each cell type (Dinter et al., 2015). Cell-type specific peptidases, as illustrated for a serine protease unique to monocytic cell line (Chateau et al., 2001), and their contribution to antigen processing and degradation are still poorly defined. The hydrolytic activities of the degradation machinery is finely tuned by external stimuli such as interferon gamma which increases the expression of certain interferon-induced peptidases such as ERAP1 or LAP, the expression of immunoproteasome catalytic subunits, TAP or MHC-I, altogether favoring the processing and display of MHC-peptides (Beninga et al., 1998; Saric et al., 2002; Serwold et al., 2002). Various stimuli relevant to HIV infection or vaccination modulate antigen processing. CD4 T cells activated with TCR-dependent or -independent stimuli present higher peptidase hydrolytic activities than resting CD4 T cells. Dendritic cells stimulated with LPS or TLR ligands 7 or 8 (such as CL097 or R848 used as adjuvants in vaccine preparation) decreased cathepsin activities while they increased all peptidases activities in macrophages. These TLR-induced alterations of peptidase activities modulated HIV antigen degradation patterns to various extents (Dinter et al., 2015, 2014). Differences in antigen degradation patterns between CD4 T cells and macrophages sustaining productive HIV infection, and DC presenting or cross-presenting HIV antigens during infection or vaccination may affect the pool of peptides available for display by MHC. Additional studies are needed to identify peptides commonly or differently processed in each cell subset, and specifically to assess whether peptides commonly processed in all cell subsets may constitute better targets for immune clearance of infected cells.

2. Sources of antigens and the MHC-peptidome in HIV infection

Owing to the technical difficulties to isolate MHC-peptides from large numbers of HIV-infected cells, limited datasets exist on the HIV-derived immunopeptidome, and all were published in the past 3 years (Yaciuk et al., 2014; Rucevic et al., 2016; Ternette et al., 2016, 2015). While the three groups used various experimental systems (cell line expressing soluble MHC, primary CD4 T cells infected with replicative HIV, B cells infected with non-replicative HIV, 293 T cells transfected with HIV, cells infected with a MVA vector expression HIV antigen fragments), they all showed that HIV-derived MHC-peptides come mostly from the structural and most abundant Gag proteins, but also from other less abundant proteins. Some areas of the Gag proteins seem efficiently presented across different cell types, HIV expression systems or HLA types. Mechanisms underlying differences in presentation of HIV peptides within Gag or across HIV proteins are still not understood despite their critical roles to identify targets for immune recognition and immunogen design. They may include variable degradation patterns of HIV proteins in various cell subsets and subcellular compartments as well as presence or absence of anchors for TAP and MHC binding.

HIV peptides presented by MHC-I included peptides of 8-11aa of optimal size for MHC-I loading, and peptides of non-canonical sizes of up to 16aa (Yaciuk et al., 2014; Rucevic et al., 2016; Ternette et al., 2016). The presentation of longer peptides is in agreement with findings on self-derived and cancer-associated peptides (Trolle et al., 2016; Remesh et al., 2017; Bassani-Sternberg et al., 2015; Ben Dror et al., 2010). The presentation of some longer peptides with extensions on the N- and/or C-terminal side was not predictable based on potential anchors for MHC-I binding. These findings raise questions about the location and loading of such peptides onto MHC, the structure of the MHC-peptide complexes and stability of the MHC-peptide at the cell surface for potential CD8 recognition. However, the unbiased identification of MHC-bound peptides led to the identification of additional responses in HIV-infected persons and will be important to define targets for immune recognition of infected cells or peptides displayed by DC after vaccination. Strategies to clear HIV reservoirs aim at reactivating latently infected cells with various latency reversal agents (LRAs) and antiretroviral therapy, leading to HIV re-expression and

peptide presentation for immune clearance (Churchill et al., 2016; Deeks et al., 2016; Margolis et al., 2016). Pre-existing HIV immune responses elicited during HIV infection may not efficiently clear LRA-reactivated reservoirs (Shan et al., 2012; Deng et al., 2015; Pollack et al., 2017). Thus, it will be important to identify HIV peptides displayed by latently infected cells after provirus reactivation with LRAs and assess whether new HIV-specific responses need to be induced in the context of therapeutic vaccination.

The antigenic sources of MHC-peptides derived from HIV may vary during viral replication but have not yet been precisely identified. Incoming virions provide functional HIV proteins for degradation in the cytosol, in endolysosomes or phagosomes leading to MHC presentation and T cell immune recognition (Dinter et al., 2015; Buseyne et al., 2001; Sacha et al., 2007). During provirus translation, in addition to complete proteins, defective ribosomal products (DRiPs) (Anton and Yewdell, 2014; Qian et al., 2005; Dolan et al., 2011) may contribute to HIV peptide presentation (Schubert et al., 2000a;b; Yewdell et al., 2001; Goldwich et al., 2008). They could contribute to providing peptides for early MHC presentation and artificially directing HIV Gag to the DRiP pathway with a N-end rule degradation signal increased MHC-I presentation of HIV (Goldwich et al., 2008). Alternate reading frame translation products of HIV such as ASP (Bet et al., 2015) have been identified in HIV-infected cells and their role in HIV replication is unknown. While these products are difficult to isolate from cells, the existence of translation products derived from alternate reading frames is indirectly demonstrated through the identification of MHC-I restricted immune responses in HIV-infected persons (Cardinaud et al., 2011, 2004), and from HLA-restricted mutations within these reading frames (Berger et al., 2015; Bansal et al., 2010; Berger et al., 2010).

Recent studies on the self MHC-peptidome revealed novel categories of unexpected sources of MHC-peptide not coming from mistakes in protein translation (Yewdell, 2007) but from abnormalities during protein degradation or peptide loading onto MHC-I (Liepe et al., 2016; Xiao et al., 2017). Spliced peptides made of two non-contiguous degradation fragments re-ligated in the proteasome during degradation were first identified in a few cancer antigens and shown to be immunogenic in patients (Vigneron et al., 2004; Warren et al., 2006; Dalet et al., 2010, 2011; Ebstein et al., 2016; Berkers et al., 2015). A recent study combining mass spectrometry and complex bioinformatics analysis (Liepe et al., 2010) showed that spliced peptides may account for up to 30% of the MHC-self-derived peptidome (Liepe et al., 2016). CD8 T cell immune responses against spliced peptides derived from Listeria were also identified in Listeria-infected mice (Platteel et al., 2016), suggesting that peptide splicing can occur during pathogen infection in vivo. A novel category of hybrid MHC-peptide was recently identified: the dual peptide occupancy of MHC-I by two short non-contiguous and separated short peptides of 2-7aa (Xiao et al., 2017). Such peptides derived from two EBV antigens generated CD8 T cell responses, suggesting that mix-and-match of short peptides occupying MHC-I groove may contribute to the MHC-peptidome (Xiao et al., 2017). It still remains to be investigated whether spliced peptides or mix-and-match peptides can be generated in HIV-infected cells, but the existence of potential new categories of unconventional peptides displayed by infected cells may help define novel HIV-specific immune responses relevant to vaccine design.

3. HIV adaptation to the antigen processing machinery and immune escape

HIV-specific CD8 and CD4 immune responses have been extensively identified in thousands of HIV-infected persons and defined in term of peptide specificity, HLA restriction, frequency of immune responses at the population level, TCR clonotypes, cytokine production, proliferative or killing capacities, yet the correlates of immune protection are still not well defined (Porichis and Kaufmann, 2011; Betts et al., 2006; Edwards et al., 2002; Chew et al., 2016; Betts et al., 2001). HIV-specific

T cells play a significant role in controlling viral load during acute infection and during spontaneous control in HIV controllers (Betts et al., 2006; Migueles et al., 2002; Almeida et al., 2007, 2009). The temporal association between the reduction of viral load in acute infection and the appearance of T cell responses (Koup et al., 1994; Borrow et al., 1994; Goonetilleke et al., 2009), and the HLA-restricted immune pressure driving HIV evolution (Allen et al., 2005; Carlson et al., 2012; Kawashima et al., 2009; Monaco et al., 2017; Carlson and Brumme, 2008) provide indirect evidence of the role of T cell in controlling viral load. However, these T cells do not clear infection. Factors contributing to their lack of efficacy include non-protective immunodominant responses (Frahm et al., 2006), immune pressure exerted by T cell responses driving mutations in the virus and immune escape (Carlson et al., 2012; Boutwell et al., 2010; Liu et al., 2013), long-term antigen stimulation leading to T cell exhaustion (Velu et al., 2015), and rapid establishment of viral reservoirs invisible to immune cells (Deeks et al., 2016; Whitney et al., 2014).

Specific HLA such HLA-B57 or -B27 and CD8 or CD4 T cell responses against Gag polyprotein (Pereyra et al., 2014, 2010; Ranasinghe et al., 2012; Altfeld et al., 2006; Johnson et al., 2015), superior multifunctional T cell responses (Betts et al., 2006; Almeida et al., 2007; Migueles et al., 2008) and subdominant rather immunodominant immune responses (Frahm et al., 2006; Borthwick et al., 2017; Hancock et al., 2015) are associated with lower viral load and spontaneous control, but the mechanisms underlying these associations to viral control are not fully understood (Walker and Yu, 2013). The search for correlates of immune protection has focused on the functionality and specificity of the CD4, CD8 T or NK cell responses elicited during infection but little is known on the contribution of antigen processing and presentation to the antiviral capacity or immunodominance of these immune responses. As T cell responses are activated through MHC-peptide recognition, fundamental outstanding questions are the nature and relative amount of HIV peptides displayed by HIV-infected cells across multiple HLAs, and how efficiently HIV-specific T cells primed during infection detect HIV peptides naturally processed and presented by infected cell subsets. No comparative datasets exist on MHC-peptide displayed by CD4 T cells, macrophages and DC of the same donor after HIV infection. Differences in antigen processing activities and degradation patterns of HIV proteins between CD4 T cells and other cell subsets (Steers et al., 2011; Dinter et al., 2015, 2014; Kourjian et al., 2016) point toward potential variations in peptide presentation. If so, the most efficient immune responses should be defined as those targeting commonly presented peptides, in addition to the already described multifunctional capacity of HIV-specific immune cells.

It will be important to identify factors driving HIV immunodominance during infection to avoid reproducing such hierarchy during vaccination. Immunodominance in viral infection is multifactorial and, depending on the epitopes, may be attributed to differences in antigen processing, TAP, MHC or TCR binding affinity (Yewdell, 2006; Chen et al., 2000). Similarly HIV T cell hierarchy may be shaped by the degradation patterns of antigens (Le Gall et al., 2007; Tenzer et al., 2009), kinetics of epitope production in cell extracts or in DC endolysosomes (Dinter et al., 2015; Lazaro et al., 2011), as well as MHC and TCR binding affinity (Iversen et al., 2006; Bronke et al., 2013; Bihl et al., 2006). Errors during retro-transcription of HIV RNA into DNA combined with HLA-restricted immune pressure lead to a diversification of HIV within a person and across the population (Allen et al., 2005; Carlson et al., 2012, 2016). Some HLA-restricted mutations reduce viral replication capacity (Brockman et al., 2007; Schneidewind et al., 2007; Peyerl et al., 2004). The impact of HLA-restricted mutations are some mitigated by additional compensatory mutations re-establishing sufficient viral fitness for propagation (Crawford et al., 2007; Carlson et al., 2014), as only limited evolution is tolerated in structurally constraint sites of HIV proteins (Peyerl et al., 2004; Schneidewind et al., 2008). Mutations preventing proper peptide recognition by T cells render many immunodominant early responses irrelevant and lead

to the broadening of immune responses in the chronic phase of infection (Karlsson et al., 2007; O'Connor et al., 2002; Allen et al., 2004). HIV has developed many mechanisms to avoid or limit its presentation to immune cells, including the down-modulation of MHC-I (Schwartz et al., 1996; Le Gall et al., 1998; Collins et al., 1998), and a remarkable adaptation to the antigen processing machinery. Many HLA-restricted intraepitopic mutations at anchor sites for MHC binding (Bronke et al., 2013) or at residues required for contact to the TCR prevent T cell recognition while degeneracy is tolerated within epitopes at sites not critical for MHC or TCR binding (Martinez-Hackert et al., 2006). More recent studies have focused on identifying patterns defining antigen processing mutations during viral evolution. A study defining residues cleavable or non-cleavable by aminopeptidases showed that mutations toward to a poorly cleavable residue reduce epitope production (Zhang et al., 2012). At the population level, residues flanking an HIV epitope tend to mutate under pressure of the restricting HLA toward poorly cleavable residues and are therefore predicable (Zhang et al., 2012). HLA-restricted mutations within epitopes observed frequently in people sharing one HLA tend to reduce intracellular peptide stability, the amount of peptides available for CTL recognition and immune escape (Lazaro et al., 2011). As intracellular peptide stability or instability is determined by specific motifs, this pattern of immune escape could be predicted in a population (Lazaro et al., 2011). Studies on antigen degradation patterns of HIV variants showed that HIV of various clades adapt to the most frequent HLAs leading to immune evasion at the population level (Ranasinghe et al., 2011; Carlson et al., 2016; Zhang et al., 2012; Tenzer et al., 2014). A better understanding of antigen degradation and development of computational tools incorporating both diversity of the degradation machinery and sequence diversity of HIV will permit us to fully identify signatures of immune escape at the population level, and conversely to define motifs associated with efficient peptide presentation.

4. Exploiting the knowledge on HIV antigen processing to improve vaccine design

The ultimate purpose of HIV research is to create vaccines to prevent infection (prophylactic vaccine) or to enhance immune functions and clear viral reservoirs in HIV-infected persons to the point where they may not need antiretroviral treatments (therapeutic vaccines) (Dalet et al., 2010; Rolland et al., 2013; Rosario et al., 2010). Vaccine trials in humans have not been successful so far at achieving these goals, but it is likely that a successful vaccine strategy will encompass both antibody responses to block viral entry and T cell responses to prevent cell-to-cell transmission or clear reservoirs (Cohen and Frahm, 2017; Tomaras and Plotkin, 2017). Multiple animal studies exploring various types of immunogens or viral vectors are showing encouraging results (Picker and Lifson, 2015; Barouch et al., 2013; Martins et al., 2017; Martins and Watkins, 2017; Barouch and Picker, 2017).

The high diversity and rapid evolution of HIV sequences within a person or across the population, the existence of different clades on different continents and the diversity of HLA combinations in the human population is a major challenge for the design of a universal HIV immunogen (Carlson et al., 2016; Burton et al., 2012; Korber et al., 2017). Vaccine strategies should avoid reproducing the narrow immunodominance of immune responses elicited during infection and increase adequacy or breadth of immune responses. Two opposite approaches are being explored to design immunogens. The first design retains only the most conserved areas of HIV proteins in the immunogen plus the most frequent variant allowing coverage of the vast majority of conserved HIV areas across clades (Ondondo et al., 2016; Nickle et al., 2007; Rolland et al., 2013). The definition of conserved areas in HIV may include both conservation of the protein sequence, co-evolving areas in which mutations dramatically reducing viral fitness loss and compensatory mutations are detected consecutively (Ondondo et al., 2016; Rolland et al., 2013; Rosario et al., 2010; Mothe et al.,

2015; Dahirel et al., 2011). Immunogens based on conserved elements encoded by a MVA-based viral vector yielded CD4, CD8 and antibody responses in mice and monkeys and clinical trials are underway to test their safety and efficacy (Borthwick et al., 2017; Rosario et al., 2010; Mothe et al., 2015; Hu et al., 2017, 2016; Borthwick et al., 2014). Alternatively, mosaic immunogen design (Korber et al., 2017; Fischer et al., 2007) aims at including sequence variability of 9-mer epitopes by computationally assembling variants in mosaic constructs. Such immunogens encoded by adenovirus-based vectors elicited T cell and antibody responses and promising results in Macaque vaccination experiments (Barouch et al., 2013) and are tested in clinical trials.

Perhaps the most intriguing and promising results in Macaque models came from a novel vaccine approach using an attenuated Rhesus CMV vector with limited cellular tropism (Picker and Lifson, 2015; Picker et al., 2012). While all Macaques vaccinated with the RhCMV expressing several complete SIV proteins developed SIV infection, 55% of them cleared SIV infection for at least 3 years post-challenge. All vaccinated Monkeys elicited broad and sustainable CD4 and CD8 T cell immune responses covering > 65% of the SIV antigens used in vaccination (Hansen et al., 2011, 2013a;b). Surprisingly CD8 T cell immune responses were restricted by MHC-II (Hansen et al., 2013a;b) and MHC-E (Hansen et al., 2016). Mechanisms underlying the priming of unconventional and broad immune responses and breaking the immunodominance observed during infection of vaccination with MVA- or adenoviral vectors expressing full proteins are still unknown. They may be related to the limited tropism of the attenuated RhCMV vector and specific cell subsets infected by the viral vectors in lymph nodes, the persistence of the antigen or any effect the vector may have on antigen processing and presentation. Whether a human CMV vector attenuated enough to be safe in the human population will trigger similar immunogenicity and clearance of HIV infection is still unknown.

These promising studies also highlight our incapacity to predict the outcome of vaccination in term of types and breadth of immune responses elicited by the vaccine and of its protectiveness after infection in the human population. They also provide guidelines for the definition of new correlates of immune protection and parameters to assess during vaccine design strategies. Immune responses elicited by the vaccine should be evaluated not only for their breadth and polyfunctionality but also to allow recognition of peptides naturally processed and presented by HIV-infected cells. It would therefore be important to assess whether vaccines processed and presented by dendritic cells lead to presentation of peptides similar or overlapping those presented by HIV-infected cells subsets. Considering the effect of viral infection (Loureiro and Ploegh, 2006) on the antigen processing machinery, it will be interesting to determine how viral vectors selected for HIV vaccines (MVA, adenoviruses, potential attenuated hCMV vector or other attenuated vectors derived from Lysteria or HSV (Im et al., 2013; Reynolds et al., 2008; Stanfield and Kousoulas, 2015) and adjuvants (Dinter et al., 2014; Cardinaud et al., 2017; Wille-Reece et al., 2006) will affect immunogen processing and presentation. It will be essential to understand how peptide presentation by DC correlates with the breadth of immune responses, and to determine if and how peptide presentation by DC may be used to predict immunogenicity before proceeding to expensive animal studies. The use of flanking motifs to modulate and optimize peptide presentation (for instance linkers inserted between conserved areas of HIV proteins for conversed elements immunogen design) may provide an additional way to improve peptide presentation by DC (Le Gall et al., 2007; Del Val et al., 1991; Eisenlohr et al., 1992; Bergmann et al., 1996). The identification of MHC-E-restricted immune responses elicited by the RhCMV vector renewed interest in the HLA-E-restricted peptidome beyond the well-known presentation of MHC-derived sequence signal in immune tolerance (Braud et al., 1997; Joosten et al., 2016; Pietra et al., 2009). One HIV peptide predicted to be presented by HLA-E (Llano et al., 1998) triggered cytolytic NK cell responses (Davis et al., 2016), supporting the role of HLA-E peptide presentation for immune clearance. A complete mapping

of the HLA-E peptidome displayed by HIV-infected cells is necessary and may identify novel relevant targets for immune clearance. How to specifically induce HLA-E-restricted HIV immune responses during vaccination remains to be determined.

The expanding understanding of HIV antigen processing mechanisms and the unbiased identification of the HIV-derived immunopeptidome, together with better computational tools to predict antigen processing and presentation in the context of antigen variability, will help define the most relevant targets for immune recognition and help improve vaccine design. Knowledge, assays and bioinformatics tools developed to tackle these HIV-focused questions will also be relevant to the design of vaccines against other chronic infections or cancer.

Acknowledgement

References

Allen, T.M., Altfeld, M., Yu, X.G., O'Sullivan, K.M., Lichterfeld, M., Le Gall, S., John, M., Mothe, B.R., Lee, P.K., Kalife, E.T., Cohen, D.E., Freedberg, K.A., Strick, D.A., Johnston, M.N., Sette, A., Rosenberg, E.S., Mallal, S.A., Goulder, P.J., Brander, C., Walker, B.D., 2004. Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J. Virol. 78, 7069–7078.

Allen, T.M., Altfeld, M., Geer, S.C., Kalife, E.T., Moore, C., O'Sullivan, K.M., Desouza, I., Feeney, M.E., Eldridge, R.L., Maier, E.L., Kaufmann, D.E., Lahaie, M.P., Reyor, L., Tanzi, G., Johnston, M.N., Brander, C., Draenert, R., Rockstroh, J.K., Jessen, H., Rosenberg, E.S., Mallal, S.A., Walker, B.D., 2005. Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J. Virol. 79, 13239–13249.

Almeida, J.R., Price, D.A., Papagno, L., Arkoub, Z.A., Sauce, D., Bornstein, E., Asher, T.E., Samri, A., Schnuriger, A., Theodorou, I., Costagliola, D., Rouzioux, C., Agut, H., Marcelin, A.G., Douek, D., Autran, B., Appay, V., 2007. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J. Exp. Med. 204, 2473–2485.

Almeida, J.R., Sauce, D., Price, D.A., Papagno, L., Shin, S.Y., Moris, A., Larsen, M., Pancino, G., Douek, D.C., Autran, B., Saez-Cirion, A., Appay, V., 2009. Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity. Blood 113, 6351–6360.

Altfeld, M., Kalife, E.T., Qi, Y., Streeck, H., Lichterfeld, M., Johnston, M.N., Burgett, N., Swart, M.E., Yang, A., Alter, G., Yu, X., Meier, A., Rockstroh, J.K., Allen, T.M., Jessen, H., Rosenberg, E., Carrington, M., Walker, B., 2006. HLA class I alleles that contribute strongly to the initial CD8++ T cell responses against HIV-1 are associated with delayed progression to AIDS. Plos Med. 3, 1851–1863.

Anton, L.C., Yewdell, J.W., 2014. Translating DRiPs: MHC class I immunosurveillance of pathogens and tumors. J. Leukocyte Biol. 95, 551–562.

Bansal, A., Carlson, J., Yan, J., Akinsiku, O.T., Schaefer, M., Sabbaj, S., Bet, A., Levy, D.N., Heath, S., Tang, J., Kaslow, R.A., Walker, B.D., Ndung'u, T., Goulder, P.J., Heckerman, D., Hunter, E., Goepfert, P.A., 2010. CD8 T cell response and evolutionary pressure to HIV-1 cryptic epitopes derived from antisense transcription. J. Exp. Med. 207, 51–59.

Barouch, D.H., Picker, L.J., 2017. Novel vaccine vectors for HIV-1. Nat. Rev. Microbiol. 15, 696.

Barouch, D.H., Stephenson, K.E., Borducchi, E.N., Smith, K., Stanley, K., McNally, A.G., Liu, J., Abbink, P., Maxfield, L.F., Seaman, M.S., Dugast, A.S., Alter, G., Ferguson, M., Li, W., Earl, P.L., Moss, B., Giorgi, E.E., Szinger, J.J., Eller, L.A., Billings, E.A., Rao, M., Tovanabutra, S., Sanders-Buell, E., Weijtens, M., Pau, M.G., Schuitemaker, H., Robb, M.L., Kim, J.H., Korber, B.T., Michael, N.L., 2013. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell 155, 531–539.

Bassani-Sternberg, M., Pletscher-Frankild, S., Jensen, L.J., Mann, M., 2015. Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation. Mol. Cell. Proteomics MCP 14, 658–673.

Ben Dror, L., Barnea, E., Beer, I., Mann, M., Admon, A., 2010. The HLA-B*2705 peptidome. Arthritis Rheum 62, 420–429.

Beninga, J., Rock, K.L., Goldberg, A., 1998. Interferon-gamma can stimulate post-proteasomal trimming of the N terminus of an antigenic peptide by inducing leucine aminopeptidase. J. Biol. Chem. 273, 18734–18742.

Berger, C.T., Carlson, J.M., Brumme, C.J., Hartman, K.L., Brumme, Z.L., Henry, L.M., Rosato, P.C., Piechocka-Trocha, A., Brockman, M.A., Harrigan, P.R., Heckerman, D., Kaufmann, D.E., Brander, C., 2010. Viral adaptation to immune selection pressure by HLA class I-restricted CTL responses targeting epitopes in HIV frameshift sequences. J. Exp. Med. 207, 61–75.

Berger, C.T., Llano, A., Carlson, J.M., Brumme, Z.L., Brockman, M.A., Cedeno, S., Harrigan, P.R., Kaufmann, D.E., Heckerman, D., Meyerhans, A., Brander, C., 2015. Immune screening identifies novel T cell targets encoded by antisense reading frames of HIV-1. J. Virol. 89, 4015–4019.

Bergmann, C.C., Yao, Q., Ho, C.K., Buckwold, S.L., 1996. Flanking residues alter antigenicity and immunogenicity of multi-unit CTL epitopes. J. Immunol. 157, 3242–3249.

Berkers, C.R., de Jong, A., Schuurman, K.G., Linnemann, C., Geenevasen, J.A., Schumacher, T.N., Rodenko, B., Ovaa, H., 2015. Peptide splicing in the proteasome creates a novel type of antigen with an isopeptide linkage. J. Immunol. 195, 4075–4084.

Bet, A., Maze, E.A., Bansal, A., Sterrett, S., Gross, A., Graff-Dubois, S., Samri, A., Guihot, A., Katlama, C., Theodorou, I., Mesnard, J.M., Moris, A., Goepfert, P.A., Cardinaud, S., 2015. The HIV-1 antisense protein (ASP) induces CD8 T cell responses during chronic infection. Retrovirology 12, 15.

Betts, M.R., Ambrozak, D.R., Douek, D.C., Bonhoeffer, S., Brenchley, J.M., Casazza, J.P., Koup, R.A., Pickler, L.J., 2001. Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J. Virol. 75, 11983–11991.

Betts, M.R., Nason, M.C., West, S.M., De Rosa, S.C., Migueles, S.A., Abraham, J., Lederman, M.M., Benito, J.M., Goepfert, P.A., Connors, M., Roederer, M., Koup, R.A., 2006. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8++ T cells. Blood 107, 4781–4789.

Bihl, F., Frahm, N., Di Giammarino, L., Sidney, J., John, M., Yusim, K., Woodberry, T., Sango, K., Hewitt, H.S., Henry, L., Linde, C.H., Chisholm 3rd, J.V., Zaman, T.M., Pae, E., Mallal, S., Walker, B.D., Sette, A., Korber, B.T., Heckerman, D., Brander, C., 2006. Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses. J. Immunol. 176, 4094–4101.

Blum, J.S., Wearsch, P.A., Cresswell, P., 2013. Pathways of antigen processing. Annu. Rev. Immunol. 31, 443–473.

Borrow, P., Lewicki, H., Hahn, B.H., Shaw, G.M., Oldstone, M.B., 1994. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68, 6103–6110.

Borthwick, N., Ahmed, T., Ondondo, B., Hayes, P., Rose, A., Ebrahimsa, U., Hayton, E.J., Black, A., Bridgeman, A., Rosario, M., Hill, A.V., Berrie, E., Moyle, S., Frahm, N., Cox, J., Colloca, S., Nicosia, A., Gilmour, J., McMichael, A.J., Dorrell, L., Hanke, T., 2014. Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol. Ther. J. Am. Soc. Gene Ther. 22, 464–475.

Borthwick, N., Lin, Z., Akahoshi, T., Llano, A., Silva-Arrieta, S., Ahmed, T., Dorrell, L., Brander, C., Murakoshi, H., Takiguchi, M., Hanke, T., 2017. Novel, in-natural-infection subdominant HIV-1 CD8+ T-cell epitopes revealed in human recipients of conserved-region T-cell vaccines. PLoS One 12.

Boutwell, C.L., Rolland, M.M., Herbeck, J.T., Mullins, J.I., Allen, T.M., 2010. Viral evolution and escape during acute HIV-1 infection. J. Infect. Dis. 202 (Suppl. 2), S309–S314.

Braud, V., Jones, E.Y., McMichael, A., 1997. The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9. Eur. J. Immunol. 27, 1164–1169.

Brockman, M.A., Schneidewind, A., Lahaie, M., Schmidt, A., Miura, T., Desouza, I., Ryvkin, F., Derdeyn, C.A., Allen, S., Hunter, E., Mulenga, J., Goepfert, P.A., Walker, B.D., Allen, T.M., 2007. Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. J. Virol. 81, 12608–12618.

Bronke, C., Almeida, C.A., McKinnon, E., Roberts, S.G., Keane, N.M., Chopra, A., Carlson, J.M., Heckerman, D., Mallal, S., John, M., 2013. HIV escape mutations occur preferentially at HLA-binding sites of CD8 T-cell epitopes. AIDS 27, 899–905.

Burton, D.R., Ahmed, R., Barouch, D.H., Butera, S.T., Crotty, S., Godzik, A., Kaufmann, D.E., McElrath, M.J., Nussenzweig, M.C., Pulendran, B., Scanlan, C.N., Schief, W.R., Silvestri, G., Streeck, H., Walker, B.D., Walker, L.M., Ward, A.B., Wilson, I.A., Wyatt, R., 2012. A blueprint for HIV vaccine discovery. Cell Host Microbe 12, 396–407.

Buseyne, F., Le Gall, S., Boccaccio, C., Abastado, J.P., Lifson, J.D., Arthur, L.O., Riviere, Y., Heard, J.M., Schwartz, O., 2001. MHC-I-restricted presentation of HIV-1 virion antigens without viral replication. Nat. Med. 7, 344–349.

Calis, J.J., Reinink, P., Keller, C., Kloetzel, P.M., Kesmir, C., 2015. Role of peptide processing predictions in T cell epitope identification: contribution of different prediction programs. Immunogenetics 67, 85–93.

Cardinaud, S., Moris, A., Fevrier, M., Rohrlich, P.S., Weiss, L., Langlade-Demoyen, P., Lemonnier, F.A., Schwartz, O., Habel, A., 2004. Identification of cryptic MHC I-restricted epitopes encoded by HIV-1 alternative reading frames. J. Exp. Med. 199, 1053–1063.

Cardinaud, S., Consiglieri, G., Bouziat, R., Urrutia, A., Graff-Dubois, S., Fourati, S., Malet, I., Guergnon, J., Guihot, A., Katlama, C., Autran, B., van Endert, P., Lemonnier, F.A., Appay, V., Schwartz, O., Kloetzel, P.M., Moris, A., 2011. CTL escape mediated by proteasomal destruction of an HIV-1 cryptic epitope. PLoS Pathog. 7, e1002049.

Cardinaud, S., Urrutia, A., Rouers, A., Coulon, P.G., Kervevan, J., Richetta, C., Bet, A., Maze, E.A., Larsen, M., Iglesias, M.C., Appay, V., Graff-Dubois, S., Moris, A., 2017. Triggering of TLR-3, -4, NOD2, and DC-SIGN reduces viral replication and increases T-cell activation capacity of HIV-infected human dendritic cells. Eur. J. Immunol. 47, 818–829.

Carlson, J.M., Brumme, Z.L., 2008. HIV evolution in response to HLA-restricted CTL selection pressures: a population-based perspective. Microbes Infect. Institut Pasteur 10, 455–461.

Carlson, J.M., Listgarten, J., Pfeifer, N., Tan, V., Kadie, C., Walker, B.D., Ndung'u, T., Shapiro, R., Frater, J., Brumme, Z.L., Goulder, P.J., Heckerman, D., 2012. Widespread impact of HLA restriction on immune control and escape pathways of HIV-1. J. Virol.

86, 5230–5243.

Carlson, J.M., Schaefer, M., Monaco, D.C., Batorsky, R., Claiborne, D.T., Prince, J., Deymier, M.J., Ende, Z.S., Klatt, N.R., DeZiel, C.E., Lin, T.H., Peng, J., Seese, A.M., Shapiro, R., Frater, J., Ndung'u, T., Tang, J., Goepfert, P., Gilmour, J., Price, M.A., Kilembe, W., Heckerman, D., Goulder, P.J., Allen, T.M., Allen, S., Hunter, E., 2014. HIV transmission. Selection bias at the heterosexual HIV-1 transmission bottleneck. Science 345, 1254031.

Carlson, J.M., Du, V.Y., Pfeifer, N., Bansal, A., Tan, V.Y., Power, K., Brumme, C.J., Kreimer, A., DeZiel, C.E., Fusi, N., Schaefer, M., Brockman, M.A., Gilmour, J., Price, M.A., Kilembe, W., Haubrich, R., John, M., Mallal, S., Shapiro, R., Frater, J., Harrigan, P.R., Ndung'u, T., Allen, S., Heckerman, D., Sidney, J., Allen, T.M., Goulder, P.J., Brumme, Z.L., Hunter, E., Goepfert, P.A., 2016. Impact of pre-adapted HIV transmission. Nat. Med. 22, 606–613.

Chateau, M.T., Robert-Hebmann, V., Devaux, C., Lazaro, J.B., Canard, B., Coux, O., 2001. Human monocytes possess a serine protease activity capable of degrading HIV-1 reverse transcriptase in vitro. Biochem. Biophys. Res. Commun. 285, 863–872.

Chauveau, L., Donahue, D.A., Monel, B., Porrot, F., Bruel, T., Richard, L., Casartelli, N., Schwartz, O., 2017. HIV fusion in Dendritic cells mainly occurs at the surface and is limited by low CD4 levels. J. Virol. 91 e01248-17.

Chen, W., Anton, L.C., Bennink, J.R., Yewdell, J.W., 2000. Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses. Immunity 12, 83–93.

Chew, G.M., Fujita, T., Webb, G.M., Burwitz, B.J., Wu, H.L., Reed, J.S., Hammond, K.B., Clayton, K.L., Ishii, N., Abdel-Mohsen, M., Liegler, T., Mitchell, B.I., Hecht, F.M., Ostrowski, M., Shikuma, C.M., Hansen, S.G., Maurer, M., Korman, A.J., Deeks, S.G., Sacha, J.B., Ndhlovu, L.C., 2016. TIGIT Marks exhausted T cells, correlates with disease progression, and serves as a target for immune restoration in HIV and SIV infection. PLoS Pathog. 12, e1005349.

Choppin, J., Cohen, W., Bianco, A., Briand, J.P., Connan, F., Dalod, M., Guillet, J.G., 2001. Characteristics of HIV-1 Nef regions containing multiple CD8++ T cell epitopes: wealth of HLA-binding motifs and sensitivity to proteasome degradation. J. Immunol. 166, 6164–6169.

Churchill, M.J., Deeks, S.G., Margolis, D.M., Siliciano, R.F., Swanstrom, R., 2016. HIV reservoirs: what, where and how to target them. Nat. Rev. Microbiol. 14, 55–60.

Cohen, K.W., Frahm, N., 2017. Current views on the potential for development of a HIV vaccine. Expert Opin. Biol. Ther. 17, 295–303.

Collins, K.L., Chen, B.K., Kalams, S.A., Walker, B.D., Baltimore, D., 1998. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 391, 397–401.

Compton, A.A., Bruel, T., Porrot, F., Mallet, A., Sachse, M., Euvrard, M., Liang, C., Casartelli, N., Schwartz, O., 2014. IFITM proteins incorporated into HIV-1 virions impair viral fusion and spread. Cell Host Microbe 16, 736–747.

Coulon, P.G., Richetta, C., Rouers, A., Blanchet, F.P., Urrutia, A., Guerbois, M., Piguet, V., Theodorou, I., Bet, A., Schwartz, O., Tangy, F., Graff-Dubois, S., Cardinaud, S., Moris, A., 2016. HIV-Infected dendritic cells present endogenous MHC class II-Restricted antigens to HIV-Specific CD4+ T cells. J. Immunol. 197, 517–532.

Crawford, H., Prado, J.G., Leslie, A., Hue, S., Honeyborne, I., Reddy, S., van der Stok, M., Mncube, Z., Brander, C., Rousseau, C., Mullins, J.I., Kaslow, R., Goepfert, P., Allen, S., Hunter, E., Mulenga, J., Kiepiela, P., Walker, B.D., Goulder, P.J., 2007. Compensatory mutation partially restores fitness and delays reversion of escape mutation within the immunodominant HLA-B*5703-restricted Gag epitope in chronic human immunodeficiency virus type 1 infection. J. Virol. 81, 8346–8351.

Dahirel, V., Shekhar, K., Pereyra, F., Miura, T., Artyomov, M., Talsania, S., Allen, T.M., Altfeld, M., Carrington, M., Irvine, D.J., Walker, B.D., Chakraborty, A.K., 2011. Coordinate linkage of HIV evolution reveals regions of immunological vulnerability. Proc. Natl. Acad. Sci. U. S. A. 108, 11530–11535.

Dalet, A., Vigneron, N., Stroobant, V., Hanada, K., Van den Eynde, B.J., 2010. Splicing of distant peptide fragments occurs in the proteasome by transpeptidation and produces the spliced antigenic peptide derived from fibroblast growth factor-5. J. Immunol. 184, 3016–3024.

Dalet, A., Robbins, P.F., Stroobant, V., Vigneron, N., Li, Y.F., El-Gamil, M., Hanada, K., Yang, J.C., Rosenberg, S.A., Van den Eynde, B.J., 2011. An antigenic peptide produced by reverse splicing and double asparagine deamidation. Proc. Natl. Acad. Sci. U. S. A. 108, E323–331.

Davis, Z.B., Cogswell, A., Scott, H., Mertsching, A., Boucau, J., Wambua, D., Le Gall, S., Planelles, V., Campbell, K.S., Barker, E., 2016. A conserved HIV-1-Derived peptide presented by HLA-E renders infected T-cells highly susceptible to attack by NKG2A/CD94-Bearing natural killer cells. PLoS Pathog. 12, e1005421.

Deeks, S.G., Lewin, S.R., Ross, A.L., Ananworanich, J., Benkirane, M., Cannon, P., Chomont, N., Douek, D., Lifson, J.D., Lo, Y.R., Kuritzkes, D., Margolis, D., Mellors, J., Persaud, D., Tucker, J.D., Barre-Sinoussi, F., A. S. T. a. c. W. G. International, Alter, G., Auerbach, J., Autran, B., Barouch, D.H., Behrens, G., Cavazzana, M., Chen, Z., Cohen, E.A., Corbelli, G.M., Eholie, S., Eyal, N., Fidler, S., Garcia, L., Grossman, C., Henderson, G., Henrich, T.J., Jefferys, R., Kiem, H.P., McCune, J., Moodley, K., Newman, P.A., Nijhuis, M., Nsubuga, M.S., Ott, M., Palmer, S., Richman, D., Saez-Cirion, A., Sharp, M., Siliciano, J., Silvestri, G., Singh, J., Spire, B., Taylor, J., Tolstrup, M., Valente, S., van Lunzen, J., Walensky, R., Wilson, I., Zack, J., 2016. International AIDS society global scientific strategy: towards an HIV cure 2016. Nat. Med. 22, 839–850.

Del Val, M., Schlicht, H.J., Ruppert, T., Reddehase, M.J., Kosinowski, U.H., 1991. Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein. Cell 66, 1145–1153.

Delamarre, L., Pack, M., Chang, H., Mellman, I., Trombetta, E.S., 2005. Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science 307, 1630–1634.

Deng, K., Pertea, M., Rongvaux, A., Wang, L., Durand, C.M., Ghiaur, G., Lai, J., McHugh, H.L., Hao, H., Zhang, H., Margolick, J.B., Gurer, C., Murphy, A.J., Valenzuela, D.M., Yancopoulos, G.D., Deeks, S.G., Strowig, T., Kumar, P., Siliciano, J.D., Salzberg, S.L., Flavell, R.A., Shan, L., Siliciano, R.F., 2015. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature 517, 381–385.

DiNapoli, S.R., Hirsch, V.M., Brenchley, J.M., 2016. Macrophages in progressive human immunodeficiency virus/Simian immunodeficiency virus infections. J. Virol. 90, 7596–7606.

Dinter, J., Gourdain, P., Lai, N.Y., Duong, E., Bracho-Sanchez, E., Rucevic, M., Liebesny, P.H., Xu, Y., Shimada, M., Ghebremichael, M., Kavanagh, D.G., Le Gall, S., 2014. Different antigen processing activities in dendritic cells, macrophages and monocytes lead to uneven production of HIV epitopes and affect CTL recognition. J. Immunol. 193, 4322–4334.

Dinter, J., Duong, E., Lai, N.Y., Berberich, M.J., Kourjian, G., Bracho-Sanchez, E., Chu, D., Su, H., Zhang, S.C., Le Gall, S., 2015. Variable processing and cross-presentation of HIV by dendritic cells and macrophages shapes CTL immunodominance and immune escape. PLoS Pathog. 11, e1004725.

Doitsh, G., Cavrois, M., Lassen, K.G., Zepeda, O., Yang, Z., Santiago, M.L., Hebbeler, A.M., Greene, W.C., 2010. Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Cell 143, 789–801.

Dolan, B.P., Li, L., Veltri, C.A., Ireland, C.M., Bennink, J.R., Yewdell, J.W., 2011. Distinct pathways generate peptides from defective ribosomal products for CD8+ T cell immunosurveillance. J. Immunol. 186, 2065–2072.

Ebstein, F., Textoris-Taube, K., Keller, C., Golnik, R., Vigneron, N., Van den Eynde, B.J., Schuler-Thurner, B., Schadendorf, D., Lorenz, F.K., Uckert, W., Urban, S., Lehmann, A., Albrecht-Koepke, N., Janek, K., Henklein, P., Niewienda, A., Kloetzel, P.M., Mishto, M., 2016. Proteasomes generate spliced epitopes by two different mechanisms and as efficiently as non-spliced epitopes. Sci. Rep. 6, 24032.

Edwards, B.H., Bansal, A., Sabbaj, S., Bakari, J., Mulligan, M.J., Goepfert, P.A., 2002. Magnitude of functional CD8+-T-cell responses to the Gag protein of HIV-1 correlates inversely with viral load in plasma. J. Virol. 76, 2298–2305.

Eisenlohr, L.C., Yewdell, J.W., Bennink, J.R., 1992. Flanking sequences influence the presentation of an endogenously synthesized peptide to cytotoxic T lymphocytes. J. Exp. Med. 175, 481–487.

Fischer, W., Perkins, S., Theiler, J., Bhattacharya, T., Yusim, K., Funkhouser, R., Kuiken, C., Haynes, B., Letvin, N.L., Walker, B.D., Hahn, B.H., Korber, B.T., 2007. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat. Med. 13, 100–106.

Frahm, N., Kiepiela, P., Adams, S., Linde, C.H., Hewitt, H.S., Sango, K., Feeney, M.E., Addo, M.M., Lichterfeld, M., Lahaie, M.P., Pae, E., Wurcel, A.G., Roach, T., St John, M.A., Altfeld, M., Marincola, F.M., Moore, C., Mallal, S., Carrington, M., Heckerman, D., Allen, T.M., Mullins, J.I., Korber, B.T., Goulder, P.J., Walker, B.D., Brander, C., 2006. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat. Immunol. 7, 173–178.

Goldwich, A., Hahn, S.S., Schreiber, S., Meier, S., Kampgen, E., Wagner, R., Lutz, M.B., Schubert, U., 2008. Targeting HIV-1 Gag into the defective ribosomal product pathway enhances MHC class I antigen presentation and CD8++ T cell activation. J. Immunol. 180, 372–382.

Goonetilleke, N., Liu, M.K., Salazar-Gonzalez, J.F., Ferrari, G., Giorgi, E., Ganusov, V.V., Keele, B.F., Learn, G.H., Turnbull, E.L., Salazar, M.G., Weinhold, K.J., Moore, S., Letvin, N., Haynes, B.F., Cohen, M.S., Hraber, P., Bhattacharya, T., Borrow, P., Perelson, A.S., Hahn, B.H., Shaw, G.M., Korber, B.T., McMichael, A.J., 2009. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J. Exp. Med. 206, 1253–1272.

Hancock, G., Yang, H., Yorke, E., Wainwright, E., Bourne, V., Frisbee, A., Payne, T.L., Berrong, M., Ferrari, G., Chopera, D., Hanke, T., Mothe, B., Brander, C., McElrath, M.J., McMichael, A., Goonetilleke, N., Tomaras, G.D., Frahm, N., Dorrell, L., 2015. Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responses. PLoS Pathog. 11.

Hansen, S.G., Ford, J.C., Lewis, M.S., Ventura, A.B., Hughes, C.M., Coyne-Johnson, L., Whizin, N., Oswald, K., Shoemaker, R., Swanson, T., Legasse, A.W., Chiuchiolo, M.J., Parks, C.L., Axthelm, M.K., Nelson, J.A., Jarvis, M.A., Piatak Jr., M., Lifson, J.D., Picker, L.J., 2011. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473, 523–527.

Hansen, S.G., Jr, M.P., Ventura, A.B., Hughes, C.M., Gilbride, R.M., Ford, J.C., Oswald, K., Shoemaker, R., Li, Y., Lewis, M.S., Gilliam, A.N., Xu, G., Whizin, N., Burwitz, B.J., Planer, S.L., Turner, J.M., Legasse, A.W., Axthelm, M.K., Nelson, J.A., Fruh, K., Sacha, J.B., Estes, J.D., Keele, B.F., Edlefsen, P.T., Lifson, J.D., Picker, L.J., 2013a. Immune clearance of highly pathogenic SIV infection. Nature 502, 100–104.

Hansen, S.G., Sacha, J.B., Hughes, C.M., Ford, J.C., Burwitz, B.J., Scholz, I., Gilbride, R.M., Lewis, M.S., Gilliam, A.N., Ventura, A.B., Malouli, D., Xu, G., Richards, R., Whizin, N., Reed, J.S., Hammond, K.B., Fischer, M., Turner, J.M., Legasse, A.W., Axthelm, M.K., Edlefsen, P.T., Nelson, J.A., Lifson, J.D., Fruh, K., Picker, L.J., 2013b. Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science 340, 1237874.

Hansen, S.G., Wu, H.L., Burwitz, B.J., Hughes, C.M., Hammond, K.B., Ventura, A.B., Reed, J.S., Gilbride, R.M., Ainslie, E., Morrow, D.W., Ford, J.C., Selseth, A.N., Pathak, R., Malouli, D., Legasse, A.W., Axthelm, M.K., Nelson, J.A., Gillespie, G.M., Walters, L.C., Brackenridge, S., Sharpe, H.R., Lopez, C.A., Fruh, K., Korber, B.T., McMichael, A.J., Gnanakaran, S., Sacha, J.B., Picker, L.J., 2016. Broadly targeted CD8(+) T cell responses restricted by major histocompatibility complex E. Science 351, 714–720.

Hu, X., Valentin, A., Dayton, F., Kulkarni, V., Alicea, C., Rosati, M., Chowdhury, B., Gautam, R., Broderick, K.E., Sardesai, N.Y., Martin, M.A., Mullins, J.I., Pavlakis, G.N., Felber, B.K., 2016. DNA prime-boost vaccine regimen to increase breadth, magnitude, and cytotoxicity of the cellular immune responses to subdominant Gag epitopes of simian immunodeficiency virus and HIV. J. Immunol. 197, 3999–4013.

Hu, X., Valentin, A., Rosati, M., Manocheewa, S., Alicea, C., Chowdhury, B., Bear, J.,

Broderick, K.E., Sardesai, N.Y., Gall, S.Le, Mullins, J.I., Pavlakis, G.N., Felber, B.K., 2017. HIV Env conserved element DNA vaccine alters immunodominance in macaques. Hum. Vaccines Immunother. 13, 2859–2871.

Im, E.J., Borducchi, E.N., Provine, N.M., McNally, A.G., Li, S., Frankel, F.R., Barouch, D.H., 2013. An attenuated Listeria monocytogenes vector primes more potent simian immunodeficiency virus-specific mucosal immunity than DNA vaccines in mice. J. Virol. 87, 4751–4755.

Iversen, A.K., Stewart-Jones, G., Learn, G.H., Christie, N., Sylvester-Hviid, C., Armitage, A.E., Kaul, R., Beattie, T., Lee, J.K., Li, Y., Chotiyarnwong, P., Dong, T., Xu, X., Luscher, M.A., MacDonald, K., Ullum, H., Klarlund-Pedersen, B., Skinhoj, P., Fugger, L., Buus, S., Mullins, J.I., Jones, E.Y., van der Merwe, P.A., McMichael, A.J., 2006. Conflicting selective forces affect T cell receptor contacts in an immunodominant human immunodeficiency virus epitope. Nat. Immunol. 7, 179–189.

Johnson, S., Eller, M., Teigler, J.E., Maloveste, S.M., Schultz, B.T., Soghoian, D.Z., Lu, R., Oster, A.F., Chenine, A.L., Alter, G., Dittmer, U., Marovich, M., Robb, M.L., Michael, N.L., Bolton, D., Streeck, H., 2015. Cooperativity of HIV-Specific cytolytic CD4 T cells and CD8 T cells in control of HIV Viremia. J. Virol. 89, 7494–7505.

Joosten, S.A., Sullivan, L.C., Ottenhoff, T.H., 2016. Characteristics of HLA-E restricted T-Cell responses and their role in infectious diseases. J. Immunol. Res. 2016, 2695396.

Karlsson, A.C., Iversen, A.K., Chapman, J.M., de Oliviera, T., Spotts, G., McMichael, A.J., Davenport, M.P., Hecht, F.M., Nixon, D.F., 2007. Sequential broadening of CTL responses in early HIV-1 infection is associated with viral escape. PLoS One 2, e225.

Kawashima, Y., Pfafferott, K., Frater, J., Matthews, P., Payne, R., Addo, M., Gatanaga, H., Fujiwara, M., Hachiya, A., Koizumi, H., Kuse, N., Oka, S., Duda, A., Prendergast, A., Crawford, H., Leslie, A., Brumme, Z., Brumme, C., Allen, T., Brander, C., Kaslow, R., Tang, J., Hunter, E., Allen, S., Mulenga, J., Branch, S., Roach, T., John, M., Mallal, S., Ogwu, A., Shapiro, R., Prado, J.G., Fidler, S., Weber, J., Pybus, O.G., Klenerman, P., Ndung'u, T., Phillips, R., Heckerman, D., Harrigan, P.R., Walker, B.D., Takiguchi, M., Goulder, P., 2009. Adaptation of HIV-1 to human leukocyte antigen class I. Nature 458, 641–645.

Kessler, J.H., Khan, S., Seifert, U., Gall, S.Le, Chow, K.M., Paschen, A., Bres-Vloemans, S.A., de Ru, A., van Montfoort, N., Franken, K.L., Benckhuijsen, W.E., Brooks, J.M., van Hall, T., Ray, K., Mulder, A., Doxiadis, I.I., van Swieten, P.F., Overkleeft, H.S., Prat, A., Tomkinson, B., Neefjes, J., Kloetzel, P.M., Rodgers, D.W., Hersh, L.B., Drijfhout, J.W., van Veelen, P.A., Ossendorp, F., Melief, C.J., 2011. Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes. Nat. Immunol. 12, 45–53.

Korber, B., Hraber, P., Wagh, K., Hahn, B.H., 2017. Polyvalent vaccine approaches to combat HIV-1 diversity. Immunol. Rev. 275, 230–244.

Koup, R.A., Safrit, J.T., Cao, Y., Andrews, C.A., McLeod, G., Borkowsky, W., Farthing, C., Ho, D.D., 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68, 4650–4655.

Kourjian, G., Xu, Y., Mondesire-Crump, I., Shimada, M., Gourdain, P., Le Gall, S., 2014. Sequence-Specific alterations of epitope production by HIV protease inhibitors. J. Immunol. 192, 3496–3506.

Kourjian, G., Rucevic, M., Berberich, M.J., Dinter, J., Wambua, D., Boucau, J., Le Gall, S., 2016. HIV protease inhibitor-induced cathepsin modulation alters antigen processing and cross-presentation. J. Immunol. 196, 3595–3607.

Law, K.M., Satija, N., Esposito, A.M., Chen, B.K., 2016. Cell-to-Cell spread of HIV and viral pathogenesis. Adv. Virus Res. 95, 43–85.

Lazaro, E., Godfrey, S.B., Stamegna, P., Ogbechie, T., Kerrigan, C., Zhang, M., Walker, B.D., Le Gall, S., 2009. Differential HIV epitope processing in monocytes and CD4 T cells affects cytotoxic T lymphocyte recognition. J. Infect. Dis. 200, 236–243.

Lazaro, E., Kadie, C., Stamegna, P., Zhang, S.C., Gourdain, P., Lai, N.Y., Zhang, M., Martinez, S.M., Heckerman, D., Le Gall, S., 2011. Variable HIV peptide stability in human cytosol is critical to epitope presentation and immune escape. J. Clin. Invest. 121, 2480–2492.

Lazaro, S., Gamarra, D., Del Val, M., 2015. Proteolytic enzymes involved in MHC class I antigen processing: a guerrilla army that partners with the proteasome. Mol. Immunol. 68, 72–76.

Le Gall, S., Erdtmann, L., Benichou, S., Berlioz, C., Liu, L.X., Heard, J.M., Schwartz, O., 1998. Nef interacts with m subunits of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC-I molecules. Immunity 8, 483–495.

Le Gall, S., Stamegna, P., Walker, B.D., 2007. Portable flanking sequences modulate CTL epitope processing. J. Clin. Invest. 117, 3563–3575.

Liepe, J., Mishto, M., Textoris-Taube, K., Janek, K., Keller, C., Henklein, P., Kloetzel, P.M., Zaikin, A., 2010. The 20S proteasome splicing activity discovered by SpliceMet. PLoS Comput. Biol. 6, e1000830.

Liepe, J., Marino, F., Sidney, J., Jeko, A., Bunting, D.E., Sette, A., Kloetzel, P.M., Stumpf, M.P., Heck, A.J., Mishto, M., 2016. A large fraction of HLA class I ligands are proteasome-generated spliced peptides. Science 354, 354–358.

Liu, M.K., Hawkins, N., Ritchie, A.J., Ganusov, V.V., Whale, V., Brackenridge, S., Li, H., Pavlicek, J.W., Cai, F., Rose-Abrahams, M., Treurnicht, F., Hraber, P., Riou, C., Gray, C., Ferrari, G., Tanner, R., Ping, L.H., Anderson, J.A., Swanstrom, R., Cohen, M., Karim, S.S., Haynes, B., Borrow, P., Perelson, A.S., Shaw, G.M., Hahn, B.H., Williamson, C., Korber, B.T., Gao, F., Self, S., McMichael, A., Goonetilleke, N., 2013. Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. J. Clin. Invest. 123, 380–393.

Llano, M., Lee, N., Navarro, F., Garcia, P., Albar, J.P., Geraghty, D.E., Lopez-Botet, M., 1998. HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer. Eur J. Immunol. 28, 2854–2863.

Llano, A., Williams, A., Olvera, A., Silva-Arrieta, S., Brander, C., 2013. Best-Characterized HIV-1 CTL epitopes: the 2013 update. In: Yusim, K., Korber, B., Brander, C., Barouch, D.H., de Boer, R., Haynes, B.F., Koup, R.A., Moore, J.P., Walker, B.D., Watkins, D.I.

(Eds.), HIV Molecular Immunology 2013. Los Alamos National Laboratory, Theoretical Biology and Biophysics, Los Alamos, New Mexico, pp. 3–19.

Loureiro, J., Ploegh, H.L., 2006. Antigen presentation and the ubiquitin-proteasome system in host-pathogen interactions. Adv. Immunol. 92, 225–305.

Marechal, V., Clavel, F., Heard, J.M., Schwartz, O., 1998. Cytosolic Gag p24 as an index of productive entry of human immunodeficiency virus type 1. J. Virol. 72, 2208–2212.

Margolis, D.M., Garcia, J.V., Hazuda, D.J., Haynes, B.F., 2016. Latency reversal and viral clearance to cure HIV-1. Science 353 aaf6517.

Martinez-Hackert, E., Anikeeva, N., Kalams, S.A., Walker, B.D., Hendrickson, W.A., Sykulev, Y., 2006. Structural basis for degenerate recognition of natural HIV peptide variants by cytotoxic lymphocytes. J. Biol. Chem. 281, 20205–20212.

Martinez-Picado, J., Deeks, S.G., 2016. Persistent HIV-1 replication during antiretroviral therapy. Curr. Opin. HIV AIDS 11, 417–423.

Martins, M.A., Watkins, D.I., 2017. What Is the predictive value of animal models for vaccine efficacy in humans? Rigorous simian immunodeficiency virus vaccine trials can be instructive. Cold Spring Harb. Perspect. Biol.

Martins, M.A., Shin, Y.C., Gonzalez-Nieto, L., Domingues, A., Gutman, M.J., Maxwell, H.S., Castro, I., Magnani, D.M., Ricciardi, M., Pedreno-Lopez, N., Bailey, V., Betancourt, D., Altman, J.D., Pauthner, M., Burton, D.R., von Bredow, B., Evans, D.T., Yuan, M., Parks, C.L., Ejima, K., Allison, D.B., Rakasz, E., Barber, G.N., Capuano 3rd, S., Lifson, J.D., Desrosiers, R.C., Watkins, D.I., 2017. Vaccine-induced immune responses against both Gag and Env improve control of simian immunodeficiency virus replication in rectally challenged rhesus macaques. PLoS Pathog. 13, e1006529.

Matsuzaki, J., Tsuji, T., Luescher, I., Old, L.J., Shrikant, P., Gnjatic, S., Odunsi, K., 2014. Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells. Cancer Immunol. Res. 2, 341–350.

McCurley, N., Mellman, I., 2010. Monocyte-derived dendritic cells exhibit increased levels of lysosomal proteolysis as compared to other human dendritic cell populations. PLoS One 5, e11949.

Migueles, S.A., Laborico, A.C., Shupert, W.L., Sabbaghian, M.S., Rabin, R., Hallahan, C.W., Van Baarle, D., Kostense, S., Miedema, F., McLaughlin, M., Ehler, L., Metcalf, J., Liu, S., Connors, M., 2002. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat. Immunol. 3, 1061–1068.

Migueles, S.A., Osborne, C.M., Royce, C., Compton, A.A., Joshi, R.P., Weeks, K.A., Rood, J.E., Berkley, A.M., Sacha, J.B., Cogliano-Shutta, N.A., Lloyd, M., Roby, G., Kwan, R., McLaughlin, M., Stallings, S., Rehm, C., O'Shea, M.A., Mican, J., Packard, B.Z., Komoriya, A., Palmer, S., Wiegand, A.P., Maldarelli, F., Coffin, J.M., Mellors, J.W., Hallahan, C.W., Follman, D.A., Connors, M., 2008. Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 29, 1009–1021.

Monaco, D.C., Ende, Z., Hunter, E., 2017. Virus-Host Gene interactions define HIV-1 disease progression. Curr. Top. Microbiol. Immunol. 407, 31–63.

Mothe, B., Hu, X., Llano, A., Rosati, M., Olvera, A., Kulkarni, V., Valentin, A., Alicea, C., Pilkington, G.R., Sardesai, N.Y., Rocafort, M., Crespo, M., Carrillo, J., Marco, A., Mullins, J.I., Dorrell, L., Hanke, T., Clotet, B., Pavlakis, G.N., Felber, B.K., Brander, C., 2015. A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques. J. Transl. Med. 13, 60.

Nickle, D.C., Rolland, M., Jensen, M.A., Pond, S.L., Deng, W., Seligman, M., Heckerman, D., Mullins, J.I., Jojic, N., 2007. Coping with viral diversity in HIV vaccine design. PLoS Comput. Biol. 3, e75.

Nielsen, M., Lundegaard, C., Lund, O., 2007. Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinform. 8, 238.

Nussbaum, A.K., Kuttler, C., Hadeler, K.P., Rammensee, H.G., Schild, H., 2001. PAProC: a prediction algorithm for proteasomal cleavages available on the WWW. Immunogenetics 53, 87–94.

O'Connor, D.H., Allen, T.M., Vogel, T.U., Jing, P., DeSouza, I.P., Dodds, E., Dunphy, E.J., Melsaether, C., Mothe, B., Yamamoto, H., Horton, H., Wilson, N., Hughes, A.L., Watkins, D.I., 2002. Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat. Med. 8, 493–499.

Ondondo, B., Murakoshi, H., Clutton, G., Abdul-Jawad, S., Wee, E.G., Gatanaga, H., Oka, S., McMichael, A.J., Takiguchi, M., Korber, B., Hanke, T., 2016. Novel conserved-region T-cell Mosaic Vaccine With High global HIV-1 coverage Is recognized by protective responses in untreated infection. Mol. Ther. J. Am. Soc. Gene Ther. 24, 832–842.

Pereyra, F., Jia, X., McLaren, P.J., Telenti, A., de Bakker, P.I., Walker, B.D., Ripke, S., Brumme, C.J., Pulit, S.L., Carrington, M., Kadie, C.M., Carlson, J.M., Heckerman, D., Graham, R.R., the International HIV controllers consortium, 2010. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330, 1551–1557.

Pereyra, F., Heckerman, D., Carlson, J.M., Kadie, C., Soghoian, D.Z., Karel, D., Goldenthal, A., Davis, O.B., DeZiel, C.E., Lin, T., Peng, J., Piechocka-Trocha, A., Carrington, M., Walker, B.D., 2014. HIV control is mediated in part by CD8+ T-cell targeting of specific epitopes. J. Virol. 88, 12937–12948.

Peyerl, F.W., Bazick, H.S., Newberg, M.H., Barouch, D.H., Sodroski, J., Letvin, N.L., 2004. Fitness costs limit viral escape from cytotoxic T lymphocytes at a structurally constrained epitope. J. Virol. 78, 13901–13910.

Picker, L.J., Lifson, J.D., 2015. HIV: seeking ultimate victory. Nature 517, 281–282.

Picker, L.J., Hansen, S.G., Lifson, J.D., 2012. New paradigms for HIV/AIDS vaccine development. Annu. Rev. Med. 63, 95–111.

Pietra, G., Romagnani, C., Moretta, L., Mingari, M.C., 2009. HLA-E and HLA-E-bound peptides: recognition by subsets of NK and T cells. Curr. Pharm. Des. 15, 3336–3344.

Platteel, A.C., Mishto, M., Textoris-Taube, K., Keller, C., Liepe, J., Busch, D.H., Kloetzel,

P.M., Sijts, A.J., 2016. CD8(+) T cells of Listeria monocytogenes-infected mice recognize both linear and spliced proteasome products. Eur. J. Immunol. 46, 1109–1118.

Pollack, R.A., Jones, R.B., Pertea, M., Bruner, K.M., Martin, A.R., Thomas, A.S., Capoferri, A.A., Beg, S.A., Huang, S.H., Karandish, S., Hao, H., Halper-Stromberg, E., Yong, P.C., Kovacs, C., Benko, E., Siliciano, R.F., Ho, Y.C., 2017. Defective HIV-1 proviruses are expressed and can be recognized by cytotoxic T Lymphocytes, which shape the proviral landscape. Cell Host Microbe 21, 494–506 e494.

Porichis, F., Kaufmann, D.E., 2011. HIV-specific CD4 T cells and immune control of viral replication. Curr. Opin. HIV AIDS 6, 174–180.

Qian, S.B., Bennink, J.R., Yewdell, J.W., 2005. Quantitating defective ribosome products. Methods Mol. Biol. 301, 271–281.

Ranasinghe, S.R., Kramer, H.B., Wright, C., Kessler, B.M., di Gleria, K., Zhang, Y., Gillespie, G.M., Blais, M.E., Culshaw, A., Pichulik, T., Simmons, A., Rowland-Jones, S.L., McMichael, A.J., Dong, T., 2011. The antiviral efficacy of HIV-specific CD8 T-cells to a conserved epitope is heavily dependent on the infecting HIV-1 isolate. PLoS Pathog. 7, e1001341.

Ranasinghe, S., Flanders, M., Cutler, S., Soghoian, D.Z., Ghebremichael, M., Davis, I., Lindqvist, M., Pereyra, F., Walker, B.D., Heckerman, D., Streeck, H., 2012. HIV-Specific CD4 T cell responses to different viral proteins have discordant associations with viral load and clinical outcome. J. Virol. 86, 277–283.

Remesh, S.G., Andreatta, M., Ying, G., Kaever, T., Nielsen, M., McMurtrey, C., Hildebrand, W., Peters, B., Zajonc, D.M., 2017. Unconventional Peptide Presentation by Major Histocompatibility Complex (MHC) Class I Allele HLA-A*02:01: BREAKING CONFINEMENT. J. Biol. Chem. 292, 5262–5270.

Reynolds, M.R., Weiler, A.M., Weisgrau, K.L., Piaskowski, S.M., Furlott, J.R., Weinfurter, J.T., Kaizu, M., Soma, T., Leon, E.J., MacNair, C., Leaman, D.P., Zwick, M.B., Gostick, E., Musani, S.K., Price, D.A., Friedrich, T.C., Rakasz, E.G., Wilson, N.A., McDermott, A.B., Boyle, R., Allison, D.B., Burton, D.R., Koff, W.C., Watkins, D.I., 2008. Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. J. Exp. Med. 205, 2537–2550.

Rolland, M., Manocheewa, S., Swain, J.V., Lanxon-Cookson, E.C., Kim, M., Westfall, D.H., Larsen, B.B., Gilbert, P.B., Mullins, J.I., 2013. HIV-1 conserved-element vaccines: relationship between sequence conservation and replicative capacity. J. Virol. 87, 5461–5467.

Rosario, M., Bridgeman, A., Quakkelaar, E.D., Quigley, M.F., Hill, B.J., Knudsen, M.L., Ammendola, V., Ljungberg, K., Borthwick, N., Im, E.J., McMichael, A.J., Drijfhout, J.W., Greenaway, H.Y., Venturi, V., Douek, D.C., Colloca, S., Liljestrom, P., Nicosia, A., Price, D.A., Melief, C.J., Hanke, T., 2010. Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. Eur. J. Immunol. 40, 1973–1984.

Rucevic, M., Kourjian, G., Boucau, J., Blatnik, R., Garcia Bertran, W., Berberich, M.J., Walker, B.D., Riemer, A.B., Le Gall, S., 2016. MHC-bound HIV peptides identified from various cell types reveal Common nested peptides and novel T cell responses. J. Virol. 90, 8605–8620.

Sacha, J.B., Chung, C., Rakasz, E.G., Spencer, S.P., Jonas, A.K., Bean, A.T., Lee, W., Burwitz, B.J., Stephany, J.J., Loffredo, J.T., Allison, D.B., Adnan, S., Hoji, A., Wilson, N.A., Friedrich, T.C., Lifson, J.D., Yang, O.O., Watkins, D.I., 2007. Gag-specific CD8+ T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J. Immunol. 178, 2746–2754.

Saric, T., Chang, S.C., Hattori, A., York, I.A., Markant, S., Rock, K.L., Tsujimoto, M., Goldberg, A., 2002. An IFN-gamma-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides. Nat. Immunol. 3, 1169–1176.

Schneidewind, A., Brockman, M.A., Yang, R., Adam, R.I., Li, B., Le Gall, S., Rinaldo, C.R., Craggs, S.L., Allgaier, R.L., Power, K.A., Kuntzen, T., Tung, C.S., LaBute, M.X., Mueller, S.M., Harrer, T., McMichael, A.J., Goulder, P.J., Aiken, C., Brander, C., Kelleher, A.D., Allen, T.M., 2007. Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J. Virol. 81, 12382–12393.

Schneidewind, A., Brockman, M.A., Sidney, J., Wang, Y.E., Chen, H., Suscovich, T.J., Li, B., Adam, R.I., Allgaier, R.L., Mothe, B.R., Kuntzen, T., Oniangue-Ndza, C., Trocha, A., Yu, X.G., Brander, C., Sette, A., Walker, B.D., Allen, T.M., 2008. Structural and functional constraints limit options for cytotoxic T-lymphocyte escape in the immunodominant HLA-B27-restricted epitope in human immunodeficiency virus type 1 capsid. J. Virol. 82, 5594–5605.

Schubert, U., Ott, D.E., Chertova, E.N., Welker, R., Tessmer, U., Princiotta, M.F., Bennink, J.R., Krausslich, H.G., Yewdell, J.W., 2000a. Proteasome inhibition interferes with Gag polyprotein processing, release, and maturation of HIV-1 and HIV-2. Proc. Natl. Acad. Sci. U. S. A. 97, 13057–13062.

Schubert, U., Anton, L.C., Gibbs, J., Norbury, C.C., Yewdell, J.W., Bennink, J.R., 2000b. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 404, 770–774.

Schwartz, O., Marechal, V., Le Gall, S., Lemonnier, F., Heard, J.M., 1996. Endocytosis of MHC-I molecules is induced by HIV-1 Nef. Nat. Med. 2, 338–342.

Schwartz, O., Marechal, V., Friguet, B., Arenzana-Seisdedos, F., Heard, J.M., 1998. Antiviral activity of the proteasome on incoming human immunodeficiency virus type 1. J. Virol. 72, 3845–3850.

Serwold, T., Gonzalez, F., Kim, J., Jacob, R., Shastri, N., 2002. ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum. Nature 419, 480–483.

Shan, L., Deng, K., Shroff, N.S., Durand, C.M., Rabi, S.A., Yang, H.C., Zhang, H., Margolick, J.B., Blankson, J.N., Siliciano, R.F., 2012. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36, 491–501.

Stanfield, B., Kousoulas, K.G., 2015. Herpes simplex vaccines: prospects of live-attenuated HSV vaccines to combat genital and ocular infections. Curr. Clin. Microbiol. Rep. 2, 125–136.

Steers, N.J., Currier, J.R., Kijak, G.H., di Targiani, R.C., Saxena, A., Marovich, M.A., Kim, J.H., Michael, N.L., Alving, C.R., Rao, M., 2011. Cell type-specific proteasomal processing of HIV-1 Gag-p24 results in an altered epitope repertoire. J. Virol. 85, 1541–1553.

Steers, N.J., Ratto-Kim, S., de Souza, M.S., Currier, J.R., Kim, J.H., Michael, N.L., Alving, C.R., Rao, M., 2012. HIV-1 envelope resistance to proteasomal cleavage: implications for vaccine induced immune responses. PLoS One 7, e42579.

Stern, L.J., Santambrogio, L., 2016. The melting pot of the MHC II peptidome. Curr. Opin. Immunol. 40, 70–77.

Tenzer, S., Peters, B., Bulik, S., Schoor, O., Lemmel, C., Schatz, M.M., Kloetzel, P.M., Rammensee, H.G., Schild, H., Holzhutter, H.G., 2005. Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding. Cell. Mol. Life Sci. 62, 1025–1037.

Tenzer, S., Wee, E., Burgevin, A., Stewart-Jones, G., Friis, L., Lamberth, K., Chang, C.H., Harndahl, M., Weimershaus, M., Gerstoft, J., Akkad, N., Klenerman, P., Fugger, L., Jones, E.Y., McMichael, A.J., Buus, S., Schild, H., van Endert, P., Iversen, A.K., 2009. Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. Nat. Immunol. 10, 636–646.

Tenzer, S., Crawford, H., Pymm, P., Gifford, R., Sreenu, V.B., Weimershaus, M., de Oliveira, T., Burgevin, A., Gerstoft, J., Akkad, N., Lunn, D., Fugger, L., Bell, J., Schild, H., van Endert, P., Iversen, A.K., 2014. HIV-1 adaptation to antigen processing results in population-level immune evasion and affects subtype diversification. Cell Rep. 7, 448–463.

Ternette, N., Block, P., Bernabeu, A.S., Borthwick, N., Pappalardo, E., Abdul-Jawad, S., Ondondo, B., Charles, P.D., Dorrell, L., Kessler, B.M., Hanke, T., 2015. Early kinetics of HLA class I-associated peptidome of MVA.HIVconsv-infected cells. J. Virol. 89, 5760–5771.

Ternette, N., Yang, H., Partridge, T., Llano, A., Cedeno, S., Fischer, R., Charles, P.D., Dudek, N.L., Mothe, B., Crespo, M., Fischer, W.M., Korber, B.T., Nielsen, M., Borrow, P., Purcell, A.W., Brander, C., Dorrell, L., Kessler, B.M., Hanke, T., 2016. Defining the HLA class I-associated viral antigen repertoire from HIV-1-infected human cells. Eur. J. Immunol. 46, 60–69.

Tomaras, G.D., Plotkin, S.A., 2017. Complex immune correlates of protection in HIV-1 vaccine efficacy trials. Immunol. Rev. 275, 245–261.

Trolle, T., McMurtrey, C.P., Sidney, J., Bardet, W., Osborn, S.C., Kaever, T., Sette, A., Hildebrand, W.H., Nielsen, M., Peters, B., 2016. The length distribution of class I-Restricted T cell epitopes Is determined by both peptide supply and MHC Allele-Specific binding preference. J. Immunol. 196, 1480–1487.

Velu, V., Shetty, R.D., Larsson, M., Shankar, E.M., 2015. Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options. Retrovirology 12, 14.

Vigneron, N., Stroobant, V., Chapiro, J., Ooms, A., Degiovanni, G., Morel, S., van der Bruggen, P., Boon, T., Van den Eynde, B.J., 2004. An antigenic peptide produced by peptide splicing in the proteasome. Science 304, 587–590.

Vyas, J.M., Van der Veen, A.G., Ploegh, H.L., 2008. The known unknowns of antigen processing and presentation. Nat. Rev. Immunol. 8, 607–618.

Walker, B.D., Yu, X.G., 2013. Unravelling the mechanisms of durable control of HIV-1. Nat. Rev. Immunol. 13, 487–498.

Warren, E.H., Vigneron, N.J., Gavin, M.A., Coulie, P.G., Stroobant, V., Dalet, A., Tykodi, S.S., Xuereb, S.M., Mito, J.K., Riddell, S.R., Van den Eynde, B.J., 2006. An antigen produced by splicing of noncontiguous peptides in the reverse order. Science 313, 1444–1447.

Whitney, J.B., Hill, A.L., Sanisetty, S., Penaloza-MacMaster, P., Liu, J., Shetty, M., Parenteau, L., Cabral, C., Shields, J., Blackmore, S., Smith, J.Y., Brinkman, A.L., Peter, L.E., Mathew, S.I., Smith, K.M., Borducchi, E.N., Rosenbloom, D.I., Lewis, M.G., Hattersley, J., Li, B., Hesselgesser, J., Geleziunas, R., Robb, M.L., Kim, J.H., Michael, N.L., Barouch, D.H., 2014. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 512, 74–77.

Wille-Reece, U., Flynn, B.J., Lore, K., Koup, R.A., Miles, A.P., Saul, A., Kedl, R.M., Mattapallil, J.J., Weiss, W., Roederer, M., Seder, R.A., 2005. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J. Exp. Med. 203, 1249–1258.

Xiao, Z., Ye, Z., Tadwal, V.S., Shen, M., Ren, E.C., 2017. Dual non-contiguous peptide occupancy of HLA class I evoke antiviral human CD8 T cell response and form neo-epitopes with self-antigens. Sci. Rep. 7, 5072.

Yaciuk, J.C., Skaley, M., Bardet, W., Schafer, F., Mojsilovic, D., Cate, S., Stewart, C.J., McMurtrey, C., Jackson, K.W., Buchli, R., Olvera, A., Cedeno, S., Plana, M., Mothe, B., Brander, C., West, J.T., Hildebrand, W.H., 2014. Direct interrogation of viral peptides presented by the class I HLA of HIV-infected T cells. J. Virol. 88, 12992–13004.

Yewdell, J.W., 2006. Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses. Immunity 25, 533–543.

Yewdell, J.W., 2007. Plumbing the sources of endogenous MHC class I peptide ligands. Curr. Opin. Immunol. 19, 79–86.

Yewdell, J.W., Schubert, U., Bennink, J.R., 2001. At the crossroads of cell biology and immunology: DRiPs and other sources of peptide ligands for MHC class I molecules. J. Cell Sci. 114, 845–851.

Zhang, S.C., Martin, E., Shimada, M., Godfrey, S.B., Fricke, J., Locastro, S., Lai, N.Y., Liebesny, P., Carlson, J.M., Brumme, C.J., Ogbechie, O.A., Chen, H., Walker, B.D., Brumme, Z.L., Kavanagh, D.G., Le Gall, S., 2012. Aminopeptidase substrate preference affects HIV epitope presentation and predicts immune escape patterns in HIV-Infected individuals. J. Immunol. 188, 5924–5934.